文献速递肝病消化道肿瘤与早癌

TESERA:基于H&E全切片图像的肝细胞癌形态学分型与预后分层

TESERA: Morphologic subtyping and prognostic stratification of hepatocellular carcinoma from H&E whole-slide images.
PubMed 文献 · Hepatology · 2026-10-02

研究开发了TESERA计算病理框架,从H&E全切片图像中无监督推导出两种组织编码亚型(TES1和TES2)并构建预后形态学指数(TESERA-MI)。在TCGA-LIHC队列中,TES2亚型总生存风险比为4.20,TES1富集代谢通路和CTNNB1突变,TES2富集增殖通路和TP53突变;TESERA-MI预测总生存风险比3.17、无病生存风险比2.19,C指数0.73,并在独立内部队列中验证了预后分层能力。

要点

  • TESERA可从常规H&E全切片图像无监督识别肝细胞癌两种形态学亚型,TES2预后较差(HR=4.20)。
  • TES1富集代谢通路和CTNNB1突变,TES2富集增殖通路和TP53突变。
  • TESERA-MI预测总生存(HR=3.17)和无病生存(HR=2.19),多变量调整后独立预后(HR=2.97)。

核心结论

  • TESERA将形态学推导的代谢-增殖亚型与外部验证的预后形态学指数统一,使常规组织学成为肝细胞癌低成本风险分层工具。

研究设计与样本

  • 计算病理框架研究,在TCGA-LIHC队列中应用无监督聚类和 supervised 模型,并在独立内部队列中验证。

主要发现

  • 无监督聚类将肿瘤分为TES1和TES2,TES2总生存风险比4.20,TES1富集代谢通路和CTNNB1突变,TES2富集增殖通路和TP53突变。
  • TESERA-MI预测总生存HR=3.17、无病生存HR=2.19,C指数0.73,1年、3年、5年AUROC分别为0.82、0.80、0.79。
  • 多变量调整后TESERA-MI独立预后HR=2.97,独立内部队列中总生存分层HR=2.16。

关键数值与推荐

  • TES2 vs TES1总生存HR=4.20;TESERA-MI预测总生存HR=3.17、无病生存HR=2.19;C指数0.73;1年、3年、5年AUROC为0.82、0.80、0.79;多变量调整后HR=2.97;独立内部队列HR=2.16。

临床怎么用

  • 可利用常规H&E全切片图像运行TESERA流程,获取形态学亚型和预后指数,辅助肝细胞癌风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) remains among the most lethal cancers worldwide, yet few tools exist to characterize HCC biology and stratify patient risk at the point of care. We developed TESERA (Tissue Encoded Subtype Elucidation and Risk Assessment), a computational pathology framework that derives both unsupervised subtypes and a prognostic index directly from hematoxylin and eosin (H&E) whole-slide images (WSIs). APPROACH AND RESULTS: Applied to The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort, unsupervised clustering of TESERA embeddings grouped tumors into Tissue Encoded Subtypes (TES1 and TES2) associated with different overall survival (OS; TES2 HR=4.20). TES1, the favorable-prognosis subtype, was enriched for metabolic pathways and CTNNB1 mutations, while TES2 was enriched for proliferative pathways and TP53 mutations. To predict patient-level survival outcomes, we trained a supervised model, the TESERA morphologic index (TESERA-MI), on TESERA embeddings, which predicted both OS (HR=3.17) and disease-free survival (HR=2.19) in TCGA-LIHC. TESERA-MI achieved the highest discrimination in a head-to-head comparison with clinical variables and molecular markers (C-index, 0.73; 1-year, 3-year, and 5-year AUROCs, 0.82, 0.80, and 0.79), remained independently prognostic after multivariable adjustment (HR=2.97), and stratified OS in an independent in-house cohort (HR=2.16). CONCLUSIONS: Released as a publicly accessible pipeline applicable to H&E WSIs, TESERA unifies morphologically derived metabolism-versus-proliferation subtypes with an externally validated, prognostic morphologic index competitive with existing clinical and molecular markers. These findings position routine histology as a low-cost, widely available substrate for biology-aware risk stratification in HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Yasaka TM, Afrin S, Chen PY, et al. TESERA: Morphologic subtyping and prognostic stratification of hepatocellular carcinoma from H&E whole-slide images. Hepatology. 2026. PMID: 42826064. doi:10.1097/HEP.0000000000001879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。